Eisai Inc - Company Profile
Powered by 
All the sales intelligence you need on Eisai Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Eisai Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Eisai Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Eisai Inc (Eisai America), a subsidiary of Eisai Co Ltd, is a pharmaceutical company that focuses on the development of solutions in the fields of neurology and oncology. The company’s research and development activities focus on therapeutic areas such as neuroscience; cancer, antibody-based programs; vascular, inflammatory, and immunological reaction. Eisai America established partnerships and collaborations with global companies such as Pfizer, Janssen Pharmaceutica Inc, Elan Pharma International Ltd, and Elan Pharmaceutical Inc for the development and distribution of drugs. Eisai America is headquartered in New Jersey, the US.
Headquarters
United States of America
Address
200 Metro Blvd, Nutley, New Jersey, 07110
Website
www.us.eisai.com
Telephone
1 201 6921100
No of Employees
832
Industry
Pharmaceuticals and Healthcare
Revenue (2025)
$2.6B
Eisai Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Levatinib | Dayvigo |
| Injection for Intravenous Use | Halaven |
| Lenvima | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In September, the company received approval for Leqembi (Lecanemab) for the treatment of Alzheimer’s disease in Australia. |
| 2025 | Corporate Changes/Expansions | In September, the company inaugurated its new state-of-the-art manufacturing facility in Baltimore. |
| 2025 | Regulatory Approval | In May, the company announced the approval of Leqembi (lecanemab) for slowing the progression of early Alzheimer’s disease in Singapore. |
Competitor Comparison
| Key Parameters | Eisai Inc | Adlyfe Inc | Ceregene Inc (Inactive) | CerFlux Inc | Research Foundation for Mental Hygiene Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Nutley | Rockville | San Diego | Birmingham | Menands |
| State/Province | New Jersey | Maryland | California | Alabama | New York |
| No. of Employees | 832 | - | - | - | - |
| Entity Type | Private | Private | Private | Private | Institution |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Katsutoshi Ido | Chief Scientific Officer | Senior Management | 2025 | - |
| Tatsuyuki Yasuno | Chairman; Chief Executive Officer | Executive Board | - | - |
| Brian Harraka | Chief Financial Officer; Vice President | Senior Management | - | - |
| Vincent Andrews | Chief Compliance Officer; General Counsel; Secretary; Senior Vice President | Senior Management | - | - |
| Lynn D. Kramer, M.D. | Chief Clinical Officer - Deep Human Biology Learning | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer